Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 29 entries
Sorted by: Best Match Show Resources per page
Which cancer survivors are at risk for a physically inactive and sedentary lifestyle? Results from pooled accelerometer data of 1447 cancer survivors.

The international journal of behavioral nutrition and physical activity

Sweegers MG, Boyle T, Vallance JK, Chinapaw MJ, Brug J, Aaronson NK, D'Silva A, Kampshoff CS, Lynch BM, Nollet F, Phillips SM, Stuiver MM, van Waart H, Wang X, Buffart LM, Altenburg TM.
PMID: 31420000
Int J Behav Nutr Phys Act. 2019 Aug 16;16(1):66. doi: 10.1186/s12966-019-0820-7.

BACKGROUND: Physical activity has beneficial effects on the health of cancer survivors. We aimed to investigate accelerometer-assessed physical activity and sedentary time in cancer survivors, and describe activity profiles. Additionally, we identify demographic and clinical correlates of physical activity,...

Cite
Sweegers MG, Boyle T, Vallance JK, et al. Which cancer survivors are at risk for a physically inactive and sedentary lifestyle? Results from pooled accelerometer data of 1447 cancer survivors. Int J Behav Nutr Phys Act. 2019;16(1):66doi: 10.1186/s12966-019-0820-7.
Sweegers, M. G., Boyle, T., Vallance, J. K., Chinapaw, M. J., Brug, J., Aaronson, N. K., D'Silva, A., Kampshoff, C. S., Lynch, B. M., Nollet, F., Phillips, S. M., Stuiver, M. M., van Waart, H., Wang, X., Buffart, L. M., & Altenburg, T. M. (2019). Which cancer survivors are at risk for a physically inactive and sedentary lifestyle? Results from pooled accelerometer data of 1447 cancer survivors. The international journal of behavioral nutrition and physical activity, 16(1), 66. https://doi.org/10.1186/s12966-019-0820-7
Sweegers, M G, et al. "Which cancer survivors are at risk for a physically inactive and sedentary lifestyle? Results from pooled accelerometer data of 1447 cancer survivors." The international journal of behavioral nutrition and physical activity vol. 16,1 (2019): 66. doi: https://doi.org/10.1186/s12966-019-0820-7
Sweegers MG, Boyle T, Vallance JK, Chinapaw MJ, Brug J, Aaronson NK, D'Silva A, Kampshoff CS, Lynch BM, Nollet F, Phillips SM, Stuiver MM, van Waart H, Wang X, Buffart LM, Altenburg TM. Which cancer survivors are at risk for a physically inactive and sedentary lifestyle? Results from pooled accelerometer data of 1447 cancer survivors. Int J Behav Nutr Phys Act. 2019 Aug 16;16(1):66. doi: 10.1186/s12966-019-0820-7. PMID: 31420000; PMCID: PMC6698042.
Copy Download .nbib Format: NLM
Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study.

Physiological reports

Toffoli EC, Sweegers MG, Bontkes HJ, Altenburg TM, Verheul HMW, van der Vliet HJ, de Gruijl TD, Buffart LM.
PMID: 34110712
Physiol Rep. 2021 Jun;9(11):e14919. doi: 10.14814/phy2.14919.

Natural killer (NK) cells are a population of innate immune cells known to play a pivotal role against tumor spread. In multiple murine models, it was shown that physical exercise had the potential to increase NK cell antitumor activity...

Cite
Toffoli EC, Sweegers MG, Bontkes HJ, et al. Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study. Physiol Rep. 2021;9(11):e14919doi: 10.14814/phy2.14919.
Toffoli, E. C., Sweegers, M. G., Bontkes, H. J., Altenburg, T. M., Verheul, H. M. W., van der Vliet, H. J., de Gruijl, T. D., & Buffart, L. M. (2021). Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study. Physiological reports, 9(11), e14919. https://doi.org/10.14814/phy2.14919
Toffoli, Elisa C, et al. "Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study." Physiological reports vol. 9,11 (2021): e14919. doi: https://doi.org/10.14814/phy2.14919
Toffoli EC, Sweegers MG, Bontkes HJ, Altenburg TM, Verheul HMW, van der Vliet HJ, de Gruijl TD, Buffart LM. Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study. Physiol Rep. 2021 Jun;9(11):e14919. doi: 10.14814/phy2.14919. PMID: 34110712; PMCID: PMC8191403.
Copy Download .nbib Format: NLM
Interventions for Improving Body Composition in Men with Prostate Cancer: A Systematic Review and Network Meta-analysis.

Medicine and science in sports and exercise

Lopez P, Newton RU, Taaffe DR, Singh F, Lyons-Wall P, Buffart LM, Tang C, Hayne D, Galvão DA.
PMID: 34935706
Med Sci Sports Exerc. 2021 Dec 21; doi: 10.1249/MSS.0000000000002843. Epub 2021 Dec 21.

PURPOSE: To perform a systematic review and network meta-analysis to investigate the most effective intervention for improving body composition outcomes in prostate cancer patients during or following treatment.METHODS: A systematic search was undertaken in multiple databases from inception to...

Cite
Lopez P, Newton RU, Taaffe DR, et al. Interventions for Improving Body Composition in Men with Prostate Cancer: A Systematic Review and Network Meta-analysis. Med Sci Sports Exerc. 2021;doi: 10.1249/MSS.0000000000002843.
Lopez, P., Newton, R. U., Taaffe, D. R., Singh, F., Lyons-Wall, P., Buffart, L. M., Tang, C., Hayne, D., & Galvão, D. A. (2021). Interventions for Improving Body Composition in Men with Prostate Cancer: A Systematic Review and Network Meta-analysis. Medicine and science in sports and exercise, . https://doi.org/10.1249/MSS.0000000000002843
Lopez, Pedro, et al. "Interventions for Improving Body Composition in Men with Prostate Cancer: A Systematic Review and Network Meta-analysis." Medicine and science in sports and exercise vol. (2021). doi: https://doi.org/10.1249/MSS.0000000000002843
Lopez P, Newton RU, Taaffe DR, Singh F, Lyons-Wall P, Buffart LM, Tang C, Hayne D, Galvão DA. Interventions for Improving Body Composition in Men with Prostate Cancer: A Systematic Review and Network Meta-analysis. Med Sci Sports Exerc. 2021 Dec 21; doi: 10.1249/MSS.0000000000002843. Epub 2021 Dec 21. PMID: 34935706.
Copy Download .nbib Format: NLM
MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing.

Oncogenesis

Neerincx M, Sie DL, van de Wiel MA, van Grieken NC, Burggraaf JD, Dekker H, Eijk PP, Ylstra B, Verhoef C, Meijer GA, Buffart TE, Verheul HM.
PMID: 26436952
Oncogenesis. 2015 Oct 05;4:e170. doi: 10.1038/oncsis.2015.29.

MicroRNAs (miRs) have been recognized as promising biomarkers. It is unknown to what extent tumor-derived miRs are differentially expressed between primary colorectal cancers (pCRCs) and metastatic lesions, and to what extent the expression profiles of tumor tissue differ from...

Cite
Neerincx M, Sie DL, van de Wiel MA, et al. MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing. Oncogenesis. 2015;4:e170doi: 10.1038/oncsis.2015.29.
Neerincx, M., Sie, D. L., van de Wiel, M. A., van Grieken, N. C., Burggraaf, J. D., Dekker, H., Eijk, P. P., Ylstra, B., Verhoef, C., Meijer, G. A., Buffart, T. E., & Verheul, H. M. (2015). MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing. Oncogenesis, 4e170. https://doi.org/10.1038/oncsis.2015.29
Neerincx, M, et al. "MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing." Oncogenesis vol. 4 (2015): e170. doi: https://doi.org/10.1038/oncsis.2015.29
Neerincx M, Sie DL, van de Wiel MA, van Grieken NC, Burggraaf JD, Dekker H, Eijk PP, Ylstra B, Verhoef C, Meijer GA, Buffart TE, Verheul HM. MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing. Oncogenesis. 2015 Oct 05;4:e170. doi: 10.1038/oncsis.2015.29. PMID: 26436952; PMCID: PMC4632090.
Copy Download .nbib Format: NLM
Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer.

JAMA network open

van Nassau SC, Bond MJ, Scheerman I, van Breeschoten J, Kessels R, Valkenburg-van Iersel LB, Verheul HM, Buffart TE, Mekenkamp LJ, Lemmens VE, Koopman M, Bol GM.
PMID: 34505885
JAMA Netw Open. 2021 Sep 01;4(9):e2124766. doi: 10.1001/jamanetworkopen.2021.24766.

IMPORTANCE: Triplet chemotherapy with fluorouracil, folinic acid, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-B) is an effective first-line treatment option for patients with metastatic colorectal cancer (mCRC). However, the degree of implementation of FOLFOXIRI-B in daily practice is unknown.OBJECTIVES: To...

Cite
van Nassau SC, Bond MJ, Scheerman I, et al. Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer. JAMA Netw Open. 2021;4(9):e2124766doi: 10.1001/jamanetworkopen.2021.24766.
van Nassau, S. C., Bond, M. J., Scheerman, I., van Breeschoten, J., Kessels, R., Valkenburg-van Iersel, L. B., Verheul, H. M., Buffart, T. E., Mekenkamp, L. J., Lemmens, V. E., Koopman, M., Bol, G. M. (2021). Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer. JAMA network open, 4(9), e2124766. https://doi.org/10.1001/jamanetworkopen.2021.24766
van Nassau, Sietske C, et al. "Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer." JAMA network open vol. 4,9 (2021): e2124766. doi: https://doi.org/10.1001/jamanetworkopen.2021.24766
van Nassau SC, Bond MJ, Scheerman I, van Breeschoten J, Kessels R, Valkenburg-van Iersel LB, Verheul HM, Buffart TE, Mekenkamp LJ, Lemmens VE, Koopman M, Bol GM. Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer. JAMA Netw Open. 2021 Sep 01;4(9):e2124766. doi: 10.1001/jamanetworkopen.2021.24766. PMID: 34505885; PMCID: PMC8433607.
Copy Download .nbib Format: NLM
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.

JAMA surgery

Rovers KP, Bakkers C, Nienhuijs SW, Burger JWA, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, van Meerten E, Tuynman JB, Kusters M, Versteeg KS, Aalbers AGJ, Kok NFM, Buffart TE, Wiezer MJ, Boerma D, Los M, de Reuver PR, Bremers AJA, Verheul HMW, Kruijff S, de Groot DJA, Witkamp AJ, van Grevenstein WMU, Koopman M, Nederend J, Lahaye MJ, Kranenburg O, Fijneman RJA, van 't Erve I, Snaebjornsson P, Hemmer PHJ, Dijkgraaf MGW, Punt CJA, Tanis PJ, de Hingh IHJT.
PMID: 34009291
JAMA Surg. 2021 Aug 01;156(8):710-720. doi: 10.1001/jamasurg.2021.1642.

IMPORTANCE: To date, no randomized clinical trials have investigated perioperative systemic therapy relative to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) alone for resectable colorectal peritoneal metastases (CPM).OBJECTIVE: To assess the feasibility and safety of perioperative systemic therapy in...

Cite
Rovers KP, Bakkers C, Nienhuijs SW, et al. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial. JAMA Surg. 2021;156(8):710-720doi: 10.1001/jamasurg.2021.1642.
Rovers, K. P., Bakkers, C., Nienhuijs, S. W., Burger, J. W. A., Creemers, G. M., Thijs, A. M. J., Brandt-Kerkhof, A. R. M., Madsen, E. V. E., van Meerten, E., Tuynman, J. B., Kusters, M., Versteeg, K. S., Aalbers, A. G. J., Kok, N. F. M., Buffart, T. E., Wiezer, M. J., Boerma, D., Los, M., de Reuver, P. R., Bremers, A. J. A., Verheul, H. M. W., Kruijff, S., de Groot, D. J. A., Witkamp, A. J., van Grevenstein, W. M. U., Koopman, M., Nederend, J., Lahaye, M. J., Kranenburg, O., Fijneman, R. J. A., van 't Erve, I., Snaebjornsson, P., Hemmer, P. H. J., Dijkgraaf, M. G. W., Punt, C. J. A., Tanis, P. J., de Hingh, I. H. J. T. (2021). Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial. JAMA surgery, 156(8), 710-720. https://doi.org/10.1001/jamasurg.2021.1642
Rovers, Koen P, et al. "Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial." JAMA surgery vol. 156,8 (2021): 710-720. doi: https://doi.org/10.1001/jamasurg.2021.1642
Rovers KP, Bakkers C, Nienhuijs SW, Burger JWA, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, van Meerten E, Tuynman JB, Kusters M, Versteeg KS, Aalbers AGJ, Kok NFM, Buffart TE, Wiezer MJ, Boerma D, Los M, de Reuver PR, Bremers AJA, Verheul HMW, Kruijff S, de Groot DJA, Witkamp AJ, van Grevenstein WMU, Koopman M, Nederend J, Lahaye MJ, Kranenburg O, Fijneman RJA, van 't Erve I, Snaebjornsson P, Hemmer PHJ, Dijkgraaf MGW, Punt CJA, Tanis PJ, de Hingh IHJT. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial. JAMA Surg. 2021 Aug 01;156(8):710-720. doi: 10.1001/jamasurg.2021.1642. PMID: 34009291; PMCID: PMC8135056.
Copy Download .nbib Format: NLM
Unique molecular signatures typify skin inflammation induced by chemical allergens and irritants.

Allergy

Lefevre MA, Nosbaum A, Rozieres A, Lenief V, Mosnier A, Cortial A, Prieux M, De Bernard S, Nourikyan J, Jouve PE, Buffat L, Hacard F, Ferrier-Lebouedec MC, Pralong P, Dzviga C, Herman A, Baeck M, Nicolas JF, Vocanson M.
PMID: 34174113
Allergy. 2021 Dec;76(12):3697-3712. doi: 10.1111/all.14989. Epub 2021 Jul 14.

BACKGROUND: Skin exposure to chemicals may induce an inflammatory disease known as contact dermatitis (CD). Distinguishing the allergic and irritant forms of CD often proves challenging in the clinic.METHODS: To characterize the molecular signatures of chemical-induced skin inflammation, we...

Cite
Lefevre MA, Nosbaum A, Rozieres A, et al. Unique molecular signatures typify skin inflammation induced by chemical allergens and irritants. Allergy. 2021;76(12):3697-3712doi: 10.1111/all.14989.
Lefevre, M. A., Nosbaum, A., Rozieres, A., Lenief, V., Mosnier, A., Cortial, A., Prieux, M., De Bernard, S., Nourikyan, J., Jouve, P. E., Buffat, L., Hacard, F., Ferrier-Lebouedec, M. C., Pralong, P., Dzviga, C., Herman, A., Baeck, M., Nicolas, J. F., & Vocanson, M. (2021). Unique molecular signatures typify skin inflammation induced by chemical allergens and irritants. Allergy, 76(12), 3697-3712. https://doi.org/10.1111/all.14989
Lefevre, Marine-Alexia, et al. "Unique molecular signatures typify skin inflammation induced by chemical allergens and irritants." Allergy vol. 76,12 (2021): 3697-3712. doi: https://doi.org/10.1111/all.14989
Lefevre MA, Nosbaum A, Rozieres A, Lenief V, Mosnier A, Cortial A, Prieux M, De Bernard S, Nourikyan J, Jouve PE, Buffat L, Hacard F, Ferrier-Lebouedec MC, Pralong P, Dzviga C, Herman A, Baeck M, Nicolas JF, Vocanson M. Unique molecular signatures typify skin inflammation induced by chemical allergens and irritants. Allergy. 2021 Dec;76(12):3697-3712. doi: 10.1111/all.14989. Epub 2021 Jul 14. PMID: 34174113.
Copy Download .nbib Format: NLM
Low-Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men With Androgenetic Alopecia and Boosts Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity.

Lasers in surgery and medicine

Mahe YF, Cheniti A, Tacheau C, Antonelli R, Planard-Luong L, de Bernard S, Buffat L, Barbarat P, Kanoun-Copy L.
PMID: 33973663
Lasers Surg Med. 2021 Nov;53(9):1208-1219. doi: 10.1002/lsm.23398. Epub 2021 May 11.

BACKGROUND AND OBJECTIVES: Low-level light therapies using visible to infrared light are known to activate several cellular functions, such as adenosine triphosphate and nitric oxide synthesis. However, few clinical observations report its biological consequences for skin and scalp homeostasis....

Cite
Mahe YF, Cheniti A, Tacheau C, et al. Low-Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men With Androgenetic Alopecia and Boosts Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity. Lasers Surg Med. 2021;53(9):1208-1219doi: 10.1002/lsm.23398.
Mahe, Y. F., Cheniti, A., Tacheau, C., Antonelli, R., Planard-Luong, L., de Bernard, S., Buffat, L., Barbarat, P., & Kanoun-Copy, L. (2021). Low-Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men With Androgenetic Alopecia and Boosts Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity. Lasers in surgery and medicine, 53(9), 1208-1219. https://doi.org/10.1002/lsm.23398
Mahe, Yann F, et al. "Low-Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men With Androgenetic Alopecia and Boosts Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity." Lasers in surgery and medicine vol. 53,9 (2021): 1208-1219. doi: https://doi.org/10.1002/lsm.23398
Mahe YF, Cheniti A, Tacheau C, Antonelli R, Planard-Luong L, de Bernard S, Buffat L, Barbarat P, Kanoun-Copy L. Low-Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men With Androgenetic Alopecia and Boosts Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity. Lasers Surg Med. 2021 Nov;53(9):1208-1219. doi: 10.1002/lsm.23398. Epub 2021 May 11. PMID: 33973663.
Copy Download .nbib Format: NLM
Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology.

Cancers

Douma JAJ, Buffart LM, Sedhom R, Labots M, Menke-van der Houven van Oordt WC, Skardhamar M, De Felice A, Lee E, Dharmaraj D, Azad NS, Carducci MA, Verheul HMW.
PMID: 34064995
Cancers (Basel). 2021 May 11;13(10). doi: 10.3390/cancers13102304.

Despite stringent eligibility criteria for trial participation, early discontinuation often occurs in phase I trials. To better identify patients unlikely to benefit from phase I trials, we investigated predictors for early trial discontinuation. Data from 415 patients with solid...

Cite
Douma JAJ, Buffart LM, Sedhom R, et al. Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology. Cancers (Basel). 2021;13(10)doi: 10.3390/cancers13102304.
Douma, J. A. J., Buffart, L. M., Sedhom, R., Labots, M., Menke-van der Houven van Oordt, W. C., Skardhamar, M., De Felice, A., Lee, E., Dharmaraj, D., Azad, N. S., Carducci, M. A., & Verheul, H. M. W. (2021). Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology. Cancers, 13(10), . https://doi.org/10.3390/cancers13102304
Douma, Joeri A J, et al. "Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology." Cancers vol. 13,10 (2021). doi: https://doi.org/10.3390/cancers13102304
Douma JAJ, Buffart LM, Sedhom R, Labots M, Menke-van der Houven van Oordt WC, Skardhamar M, De Felice A, Lee E, Dharmaraj D, Azad NS, Carducci MA, Verheul HMW. Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology. Cancers (Basel). 2021 May 11;13(10). doi: 10.3390/cancers13102304. PMID: 34064995; PMCID: PMC8151105.
Copy Download .nbib Format: NLM
Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases.

Clinical colorectal cancer

Hellingman T, Kuiper BI, Buffart LM, Meijerink MR, Versteeg KS, Swijnenburg RJ, van Delden OM, Haasbeek CJA, de Vries JJJ, van Waesberghe JHTM, Zonderhuis BM, van der Vliet HJ, Kazemier G.
PMID: 34462211
Clin Colorectal Cancer. 2021 Dec;20(4):e263-e272. doi: 10.1016/j.clcc.2021.07.007. Epub 2021 Jul 26.

BACKGROUND: A uniform treatment strategy for patients suffering from early recurrence after local treatment of CRLM is currently lacking. The aim of this observational cohort study was to assess the potential survival benefit of repeat local treatment compared to...

Cite
Hellingman T, Kuiper BI, Buffart LM, et al. Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases. Clin Colorectal Cancer. 2021;20(4):e263-e272doi: 10.1016/j.clcc.2021.07.007.
Hellingman, T., Kuiper, B. I., Buffart, L. M., Meijerink, M. R., Versteeg, K. S., Swijnenburg, R. J., van Delden, O. M., Haasbeek, C. J. A., de Vries, J. J. J., van Waesberghe, J. H. T. M., Zonderhuis, B. M., van der Vliet, H. J., & Kazemier, G. (2021). Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases. Clinical colorectal cancer, 20(4), e263-e272. https://doi.org/10.1016/j.clcc.2021.07.007
Hellingman, Tessa, et al. "Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases." Clinical colorectal cancer vol. 20,4 (2021): e263-e272. doi: https://doi.org/10.1016/j.clcc.2021.07.007
Hellingman T, Kuiper BI, Buffart LM, Meijerink MR, Versteeg KS, Swijnenburg RJ, van Delden OM, Haasbeek CJA, de Vries JJJ, van Waesberghe JHTM, Zonderhuis BM, van der Vliet HJ, Kazemier G. Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases. Clin Colorectal Cancer. 2021 Dec;20(4):e263-e272. doi: 10.1016/j.clcc.2021.07.007. Epub 2021 Jul 26. PMID: 34462211.
Copy Download .nbib Format: NLM
Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis.

Prostate cancer and prostatic diseases

Lopez P, Newton RU, Taaffe DR, Singh F, Buffart LM, Spry N, Tang C, Saad F, Galvão DA.
PMID: 34420038
Prostate Cancer Prostatic Dis. 2021 Aug 21; doi: 10.1038/s41391-021-00442-0. Epub 2021 Aug 21.

BACKGROUND: To systematically review and analyse the associations between fat and muscle mass measures with overall survival in men with prostate cancer.METHODS: A systematic search was conducted in CINAHL, Cochrane Library, EMBASE, PubMed, and Web of Science databases from...

Cite
Lopez P, Newton RU, Taaffe DR, et al. Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis. Prostate Cancer Prostatic Dis. 2021;doi: 10.1038/s41391-021-00442-0.
Lopez, P., Newton, R. U., Taaffe, D. R., Singh, F., Buffart, L. M., Spry, N., Tang, C., Saad, F., & Galvão, D. A. (2021). Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis. Prostate cancer and prostatic diseases, . https://doi.org/10.1038/s41391-021-00442-0
Lopez, Pedro, et al. "Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis." Prostate cancer and prostatic diseases vol. (2021). doi: https://doi.org/10.1038/s41391-021-00442-0
Lopez P, Newton RU, Taaffe DR, Singh F, Buffart LM, Spry N, Tang C, Saad F, Galvão DA. Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis. Prostate Cancer Prostatic Dis. 2021 Aug 21; doi: 10.1038/s41391-021-00442-0. Epub 2021 Aug 21. PMID: 34420038.
Copy Download .nbib Format: NLM
Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancer.

Oral oncology

Poel D, Rustenburg F, Sie D, van Essen HF, Eijk PP, Bloemena E, Elhorst Benites T, van den Berg MC, Vergeer MR, Leemans RC, Buffart TE, Ylstra B, Brakenhoff RH, Verheul HM, Voortman J.
PMID: 32585557
Oral Oncol. 2020 Jun 22;109:104851. doi: 10.1016/j.oraloncology.2020.104851. Epub 2020 Jun 22.

OBJECTIVES: The majority of patients with locally advanced larynx or hypopharynx squamous cell carcinoma are treated with organ-preserving chemoradiotherapy (CRT). Clinical outcome following CRT varies greatly. We hypothesized that tumor microRNA (miRNA) expression is predictive for outcome following CRT.METHODS:...

Cite
Poel D, Rustenburg F, Sie D, et al. Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancer. Oral Oncol. 2020;109:104851doi: 10.1016/j.oraloncology.2020.104851.
Poel, D., Rustenburg, F., Sie, D., van Essen, H. F., Eijk, P. P., Bloemena, E., Elhorst Benites, T., van den Berg, M. C., Vergeer, M. R., Leemans, R. C., Buffart, T. E., Ylstra, B., Brakenhoff, R. H., Verheul, H. M., & Voortman, J. (2020). Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancer. Oral oncology, 109104851. https://doi.org/10.1016/j.oraloncology.2020.104851
Poel, Dennis, et al. "Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancer." Oral oncology vol. 109 (2020): 104851. doi: https://doi.org/10.1016/j.oraloncology.2020.104851
Poel D, Rustenburg F, Sie D, van Essen HF, Eijk PP, Bloemena E, Elhorst Benites T, van den Berg MC, Vergeer MR, Leemans RC, Buffart TE, Ylstra B, Brakenhoff RH, Verheul HM, Voortman J. Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancer. Oral Oncol. 2020 Jun 22;109:104851. doi: 10.1016/j.oraloncology.2020.104851. Epub 2020 Jun 22. PMID: 32585557.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 29 entries